TScan Therapeutics, Inc. (TCRX) has 24 open-market insider trades by 11 insiders since 2021. The most active filer is Brian M. Silver, CFO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| 667, L.P. | Dir10% Owner | — | 2 | $26.2M | 2024-04-19 |
| Lynx1 Capital Management LP | 10% Owner | — | 3 | $5.1M | 2025-12-23 |
| Christoph H. Westphal | 10% Owner | — | 1 | $2.0M | 2021-07-20 |
| Zoran Zdraveski | — | — | 2 | $1.9M | 2024-08-23 |
| Timothy J. Barberich | Dir | — | 2 | $483K | 2023-12-19 |
| Weston Nichols | 10% Owner | — | 2 | $390K | 2024-12-26 |
| David P. Southwell | CEO | — | 2 | $186K | 2022-05-18 |
| Brian M. Silver | CFO | — | 5 | $157K | 2022-12-28 |
| Barbara Klencke | Dir | — | 3 | $108K | 2024-09-23 |
| Gavin MacBeath | Chief Scientific Officer | — | 1 | $31K | 2021-09-21 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner | Buy | $218K | 2025-12-19 |
| Lynx1 Capital Management LP | 10% Owner | Buy | $4.8M | 2025-05-19 |
| Weston Nichols | 10% Owner | Buy | $386K | 2024-12-12 |
| Weston Nichols | 10% | Buy | $4K | 2024-11-15 |
| Barbara Klencke | Director | Buy | $26K | 2024-09-23 |
| Zoran Zdraveski | — | Sell | $1.9M | 2024-08-23 |
Companies that share insiders with TCRX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Barbara Klencke | Director | Buy | $56K | 2024-08-23 |
| Timothy J. Barberich | Director | Buy | $284K | 2023-12-18 |
| Barbara Klencke | Director | Buy | $25K | 2023-12-14 |
| Timothy J. Barberich | Director | Buy | $199K | 2023-06-02 |
| Lynx1 Capital Management LP | 10% | Sell | $64K | 2023-05-31 |
| Brian M. Silver | CFO | Buy | $9K | 2022-12-27 |
| David P. Southwell | CEO | Buy | $90K | 2022-05-18 |
| 667, L.P. | Director & 10% Owner | Buy | $4.8M | 2022-05-10 |
| Brian M. Silver | CFO | Buy | $51K | 2022-03-24 |